Cara Therapeutics launches late-stage study of CR845 in CKD-aP [Seeking Alpha]
Cara Therapeutics, Inc. (CARA)
Last cara therapeutics, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.caratherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
Cara Therapeutics launches late-stage study of CR845 in CKD-aPCara Therapeutics (NASDAQ:CARA)initiates a Phase 3 clinical trial assessing lead candidate IV CR845, branded as KORSUVA (difelikefalin), in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKP-aP), an intractable, intense systemic itch condition. The indication has Breakthrough Therapy status.The randomized, double-blind, placebo-controlled study will have a 12-week treatment period followed by a 52-week open-label extension period. It will evaluate the safety and efficacy of 0.5 mcg/kg of KORSUVA in 350 subjects. The primary endpoint will be proportion of patients achieving at least a three-point improvement from baseline in the weekly average of daily 24-hour itching intensity numeric rating scale (NRS) scores at week 12.KORSUVA is a peripherally actingkappa opioid receptor agonist that is also being developed for the treatment of acute and chronic pain. Its value proposition is op
Show less
Read more
Impact Snapshot
Event Time:
CARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARA alerts
High impacting Cara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARA
News
- Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Uremic Pruritus Pipeline Insight 2024, Featuring Key Players Cara Therapuetics and Lumosa Therapeutics, and Key Emerging Drugs Cara Therapeutics CR845 and Lumos Therapeutics' LT 5001 [Yahoo! Finance]Yahoo! Finance
- Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
CARA
Earnings
- 3/4/24 - Beat
CARA
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form ARS
- 4/22/24 - Form DEF
- CARA's page on the SEC website